33rd international symposium on ALS/MND

Virtual

6 - 9 December 2022

Programme

Organised by the Motor Neurone Disease Association in co-operation with the International Alliance of ALS/MND Associations
Organiser of the Symposium:

Motor Neurone Disease Association
Francis Crick House, 6 Summerhouse Road
Moulton Park, Northampton NN3 6BJ

Held in co-operation with:

The International Alliance of ALS/MND Associations
Email: alliance@als-mnd.org
Website: www.alsmndalliance.org
Welcome to the 33rd annual symposium on ALS/MND, which for the third year in a row is being held online.

In the Harry Potter stories, Harry begins with no knowledge of his magical abilities, but as time goes on, he discovers how to wield them and use them to achieve his ends. Our understanding of ALS has followed a similar trajectory. We started with very little insight as to why ALS happens or how to intervene to stop it, but bit by bit we are making progress through science, building on our knowledge to develop new tools to find significant therapies. Initially, Harry could only use one spell at a time to defend his pals, but as his knowledge improved, he was able to simultaneously use many. Similarly, for many years we have had only one or two clinical trials to offer our patients at any one time, but now we have multiple trials, using varied approaches. Like Harry, we are achieving this progress with the help of many others, all working to the same goal – and we can see our friends and colleagues in this international symposium, bringing together researchers from across the globe.

Although the buzz and benefits of an in-person meeting cannot be replicated by a remote conference, we have done our best to mitigate and to capture that feeling as far as possible. A virtual symposium also means that people who would otherwise have difficulty attending are able to participate. This year, we showcase exciting advances in research through the entire pathway from discovery science to translation into meaningful treatments.

A major theme is neuroinflammation, its role in sporadic and familial ALS and the outcomes of therapies to tackle it. The design of clinical trials, and the outcome of a number of different approaches to treatment are also two big subjects. They are likely to feature more heavily over the next few years.

Genetics and other risk and modifier factors are always a major focus, but bioinformatics and AI are featuring more and more, as conventional methods for identifying genetic variants and environmental factors that influence ALS and ALS risk are exhausted.

Three more prominent and increasingly important topics this year are the role of metabolism in ALS, the role of RNA and protein processing, and the modelling of non-genetic ALS in the laboratory, something that has been challenging and largely missing from our armoury of research tools.

The International Symposium on ALS/MND is a major annual event for the ALS community, bringing scientists and clinical practitioners together to evidence the progress being made to cure ALS/MND. I wish you a very informative and enjoyable meeting.

Ammar Al-Chalabi
Programme Committee Chair
Tuesday 6 December 2022

SESSION 1

OPENING SESSION

Chairs: B Dickie (UK) A Al-Chalabi (UK)

13.45 – 13.50  Welcome – B Dickie (UK) and A Al-Chalabi (UK)

13.50 – 14.35  The Stephen Hawking Memorial Lecture

Introduction  

C01 The contribution of aging to neurodegenerative disease  
L Hawking (UK)  
F Gage (USA)

14.35 – 14.45  Discussion/Questions

14.45 – 14.55  International Alliance Humanitarian Award

Forbes Norris and Humanitarian Awards

14.55 – 15.10  IPG Award and winner’s research presentation

15.10 – 15.40  ICEBREAKER SESSION

SESSION 2

CLINICAL TRIALS

Chairs: K Talbot (UK) B Dickie (UK)

1540 – 1600  C02 Results from a randomized, double-blind, placebo-controlled trial of RNS60 in people with ALS  
E Pupillo (Italy)

1600 – 1620  C03 Modifying immune response and outcomes in ALS (MIROCALS): design and results of a phase 2b, double-blind randomized placebo-controlled trial of low dose interleukin-2 (ld IL2) in ALS  
G Bensimon (France)

1620 – 1630  C04 Evidence for a survival benefit in ALS with CNM-Au8 treatment: interim results from the RESCUE-ALS trial long-term open extension  
S Vucic (Australia)

1630 – 1640  C05 Evaluating efficacy and safety of Tofersen in adults with SOD1 ALS: Results from the Phase 3 VALOR trial and open label extension  
T Miller (USA)

1640 – 1655  Discussion/Questions

16.55 - 17.05  BREAK

Please note that all timings are GMT
**LIVE POSTER SESSION A**

**17.05 – 18.35 GMT**

**EPI-01** Frequency of mutations in C9orf72, SOD1, FUS, and TARDBP genes among amyotrophic lateral sclerosis cases: a review and meta-analysis  
Ms Julie Barberio

**EPI-02** Lessons Learned from Survival Modeling in an Expanded Access Protocol  
Mr Alex Berger

**EPI-03** The Canadian Neuromuscular Disease Registry: A national ALS registry for real world evidence  
Dr Victoria Hodgkinson

**EPI-04** Detection of spatial association between ALS and airborne lead (Pb) in Ohio  
Dr Meifang Li

**GEN-01** A case of an uncommon late onset of ALS associated with an undescribed SOD1 mutation  
Dr Lucrezia Becattini

**GEN-02** A novel mutation in ZFYVE26 gene (c.195-1G>A) in a young manafactured by spastic paraplegia  
Dr Alessandro Bombaci

**GEN-03** Genetic testing of people with early-onset MND in the West of Scotland  
Dr Fraser Brown

**GEN-04** The Role of Nicotinic Receptor Genes (CHRN) in Amyotrophic Lateral Sclerosis  
Dr Filippo De Mattei

**GEN-05** Withdrawn

**GEN-06** Genetics in ALS: A change in attitude, no change in results.  
Dr Ana Sanchez Fernandez

**GEN-07** A Genome-wide association study on the New England and Ohio Amyotrophic Lateral Sclerosis Cohort  
Mr Jiang Gui

**GEN-08** Unraveling Clinico-Pathological Heterogeneity in Motor Neuron Diseases using Long-Read Sequencing  
Ms Angita Jain

**IVT-01** Superoxide Dismutase-1 Alterns the Rate of Prion Protein Aggregation and Resulting Fibril Formation  
Miss Kamile Mikalauskaite

**IVT-02** Investigating variants in NUP50 as risk factors for Amyotrophic Lateral Sclerosis  
Ms Olga Roman

**IVT-03** Effect of complement C3 inhibition in an iPSC-derived ALS neuromuscular junction model of neuroinflammation  
Dr Scott Baver

**IVT-04** Characterization of PP1A/EMMPRIN Pathway in Familial Models of Amyotrophic Lateral Sclerosis.  
Mrs Gloria Nwamaka Edozie

**IVT-05** Cellular function of hnRNP A1B, a longer HNRNPA1 isoform  
Miss Mariana Lasera Ballester

**IVT-06** The interactors of FUS  
Dr Helena Motlai

**IVV-01** Mapping PHD1-mediated neuroprotection in mutant SOD1 ALS mice at single-cell resolution.  
Ms Christine Gervens

**IVV-02** Sympathetic neurons are additional cell types affected in Amyotrophic Lateral Sclerosis.  
Mrs Gloria Nwamaka Edozie

**IVV-03** Novel insights on the role and therapeutic potential of Glycoprotein nonmetastatic melanoma protein B(Gpnmb) in Amyotrophic Lateral Sclerosis.  
Dr Mauro Giuseppe Spatafora

**IVV-04** Investigating ASO therapeutic strategies in targeting the ALS-causing FUSRS21H variant using zebrafish  
Mr Rampal Christian

**IVV-05** Zebrafish TDP-43 knock-in CRISPR mutants develop a robust ALS-like phenotype independent of TDP-43 mislocalization  
Mr Ziyaan Harji

**IVV-06** Loss of C9orf72 induces neurodegeneration and autophagic deficits in a mouse model of TDP-43 proteinopathy  
Ms Lilian Lin

**HCB-01** Intracellular transport and mitochondrial bioenergetics are reduced in IPS-derived motor neurons from ALS patients with TDP-43 mutations  
Dr Ruxandra Dafinca

**HCB-02** Formyl Peptide Receptor-Like 1 Depleted Monocytes in Amyotrophic Lateral Sclerosis  
Mr Guy Hunt

**HCB-03** Phosphorylation of Y526 FUS in FTD  
Professor Boris Rogelj

**HCB-04** ALS fibroblasts derived-exosomes increase wound healing  
Mr Vincent Clément

**HCB-05** Human motor neurons with mutations in TARDBP (TDP-43) derived from gene-edited iPSCs recapitulate features of ALS in vitro  
Ms Sarah Lépine

**HCB-06** A C-terminally truncated TDP-43 splice isoform exhibits neuronal specific cytoplasmic aggregation and contributes to TDP-43 pathology in ALS  
Mr Marc Shenouda

**BIO-01** Withdrawn

**BIO-02** Creatinine Kinase-MB as a Complementary Biomarker in the Evaluation of Patients with Amyotrophic Lateral Sclerosis  
Dr Sergio Castro-Gomez

**BIO-03** Chitinase dysregulation predicts ALS disease aggressiveness and stems from multiple CNS populations  
Ms Nayana Gaur

**BIO-04** Blood Neutrophil-to-Lymphocyte ratio predict Survival in ALS patients  
Miss Diana Monteiro Lopes

**TST-01** Nicotinamide riboside, pterostilbene and ibudilast delay ALS progression in murine models  
Professor Elena Obrador

**TST-02** Combination therapy approaches for the treatment of Amyotrophic Lateral Sclerosis  
Mrs Megan Baird

**TST-03** How Much Do Patients Know About Basic Research? A Survey of Knowledge and Preferences Among People Living with ALS and Other Neurological Conditions  
Professor Danielle Boyce
TST-04 Development of an UNC13A cryptic exon skipping antisense oligonucleotide as a treatment for ALS and FTD
Dr Wen-Hsuan Chang

TST-05 Small Molecule Hepatocyte Growth Factor (HGF)/MET Positive Modulator ATH-1105 is Neuroprotective in the TDP-43 Mouse Model of Amyotrophic Lateral Sclerosis
Dr Kevin Church

TST-06 Discovery and Development of Inhibitors of 15-Lipoxygenase to Reduce Ferroptosis-Induced Injury for ALS and Neurodegenerative Diseases
Mr Jeff Trimmer

IMG-01 Motor Imagery in Amyotrophic Lateral Sclerosis: an fMRI study of postural control
Ms Malek Abidi

IMG-02 Loss of brainstem white matter predicts onset and motor neuron symptoms in C9orf72 expansion carriers: a GENFI study
Mr Sergi Borrego - Écija

IMG-03 Brain-age predicts survival in ALS
Professor Andreas Hermann

CLT-01 Independent Expert Review of Cardiac Adverse Events and Electrocardiographic Abnormalities and Parameters in a Phase 2 Trial of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (CENTAUR)
Dr Jamie Timmons

CLT-02 Tegoprubart (AT-1501) is safe and well tolerated and reduces inflammation in patients with ALS
Dr Jeffrey Bornstein

CLT-03 Clinical Trial Operations for the HEALEY ALS Platform Trial
Ms Marianne Chase

CLT-04 A variant-selective approach in C9orf72-associated amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD): Results from the FOCUS-C9 clinical trial
Dr Kenechi Ejebe

CLT-05 Longitudinal comparison of the self-entry amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS-RSE) and rasch-built overall amyotrophic lateral sclerosis disability scale (ROADS) as outcome measures in people with amyotrophic lateral sclerosis
Dr Stephen Johnson

CLT-06 Wearable and smartphone devices can track ALS disease progression and may serve as novel clinical trial outcome measures
Dr Marta Karas

CLT-07 Expanded Access to Sodium Phenylbutyrate and Taurursodiol Coformulation in Amyotrophic Lateral Sclerosis: Updates and Initial Learnings
Mr Philip Green

CLT-08 QRL-201-01 - A multi-center, randomized, double-blind, placebo-controlled multiple-ascending dose study to evaluate the safety and tolerability of QRL-201 in amyotrophic lateral sclerosis
Ms Kristiana Salmon

COG-01 Making Sense: An online Meaning Centred Psychological intervention for individuals with MND
Mrs Sandra de Moree

COG-02 Clinicoanatomical substrates of selfish behaviour in amyotrophic lateral sclerosis – an observational cohort study
Professor Dorothee Lule

COG-03 A novel EEG paradigm to quantify the cortical network dysfunction underpinning verbal fluency impairments in ALS
Ms Serena Piaiota

CMS-01 IMPACT ALS EUROPE SURVEY - People living with ALS in Europe
Miss Éilís Conroy

CMS-02 Understanding family experiences of inherited MND: qualitative interview study and new resource on healthtalk.org
Miss Jade Howard

CMS-03 A multi-centre evaluation of post-gastrostomy management in motor neuron disease (PostGas) to understand why patients often experience poor nutritional outcomes following placement of a feeding tube
Miss Lucy Musson

CMS-04 Critical Resources for Underserved Veterans with ALS - Combating Deserts of Care
Mrs Mandi Bailey

CMS-05 CBAS: Ongoing Data Collection & Validation
Professor Laura Ball

CMS-06 At-Home Telespirometry (AHT) In Amyotrophic Lateral Sclerosis (ALS) Implementation Science: Evidence-Based Development of Vital Capacity (VC) Measurement Frequency Algorithm for Clinical Testing
Professor Benjamin Rix Brooks

CMS-07 WITHDRAWN

CMS-08 Proximity to UCSF ALS Satellite Clinics Increases Rural Patient Access and Clinic Visit Frequency, But Disparities Remain
Dr Jill Goslinga

CMS-09 Equipment for Living with ALS: Results from the ALS Focus Mobility Survey
Dr Sarah Parvanta
Wednesday 7 December 2022

LIVE POSTER SESSION B

12.15 – 13.45 GMT

EPI-05 A Review of the Efficacy of Edaravone and the Factors That Influence its Response in Patients With Amyotrophic Lateral Sclerosis
Miss Maleesha Jayasinghe

EPI-06 WITHDRAWN

EPI-07 ‘He’s been brave for me and I’ve been brave for him’ meaning in life and personal satisfaction as positive aspects for ALS caregivers – A longitudinal mixed methods analysis
Miss Éilís Conroy

EPI-08 Exposure to electromagnetic fields does not modify neither the onset age nor the disease progression in ALS patients
Dr Margherita Daviddi

GEN-09 WITHDRAWN

GEN-10 Study into a possible common founder effect for the SOD1 p.V48A mutation amongst Malaysian Chinese and Mainland Chinese ALS patients
Miss Suzanna Edgar

GEN-11 Comprehensive genetic study of genes that alter NAD+ levels in Australian sporadic amyotrophic lateral sclerosis
Dr Jennifer Fifita

GEN-12 Prediction of pathogenicity of ALS-causing gene missense variants using structural information predicted by AlphaFold2
Mr Yuya Hatano

GEN-13 Sex-stratified analysis of ~133k samples identifies novel associations with Amyotrophic Lateral Sclerosis
Dr Ross Byrne

GEN-14 Whole-genome sequencing reveals that variants in the IL18RAP 3’UTR protect against ALS
Dr Chen Eitan

GEN-15 Genetic analysis of ALS in Russia
Miss Alina Korbut

GEN-16 Genome-wide association study of rare variants in ERV-elements of ALS patients: age at onset of ALS may be regulated by MLT1B ERV-element.
Dr Alexey Shatunov

IVT-07 Dysregulation of SFPQ in motor neuron disease
Dr Alison Hogan

IVT-08 Dysregulation of cellular energy metabolism and axonal transport in TDP-43 M337V mESC-derived motor neurons
Miss Emily Carroll

IVT-09 TBK1 kinase inhibition is associated with cell autonomous microglial dysfunction
Miss Uroosa Chughtai

IVT-10 Mechanistic insights into the cause of DNA damage accumulation in cells bearing TDP-43 and FUS cytoplasmic inclusions
Miss Stefania Modafferi

IVT-11 Characterization of iPSC-motoneurons from a HSP patient with a novel mutation in KIF5A N-terminal region
Dr Serena Santangelo

IVV-08 Synergistic activity of a nerve-muscle, multimodal combination therapy in mutant SOD1 mice
Professor Peter Crouch

IVV-09 Longer telomeres are present in a mouse model of amyotrophic lateral sclerosis displaying TDP-43 pathological features
Dr Anna Konopka

IVV-10 The Serum Response Factor (SRF) regulates motoneuron vulnerability in ALS through the regulation of autophagy flux
Miss Natalie Yashoda Dikwella

IVV-11 The increased expression of neuregulin-1 type III in neurons in double transgenic mice does not improve ALS-related pathology or extend the lifespan of SOD1G93A mice
Dr Sara Hernández

IVV-12 Exploring the clinical relevance of compound muscle action potential data in the SOD1G93A mouse
Mr Scott McKinnon

HCB-07 Evaluating models of Motor Neuron Disease molecule by molecule.
Dr Dezerae Cox

HCB-08 Immunological characterization of spinal cord organoids derived from sALS patients
Dr Matteo Bordoni

HCB-09 ALS/FTD-associated C9orf72 C4G2 repeat RNA binds to FARS protein and affect the rate of phenylalanine-tRNA aminoacylation
Ms Urša Čerček

HCB-10 RNA G-quadruplex structures regulate stress granule dynamics
Mr Yehuda-Matari Danino

HCB-11 Towards a quantitative protein atlas of human iMN and their extracellular vesicles
Dr Raquel Mesquita-Ribeiro

HCB-12 HuD gain-of-function leads to disruption of the neuromuscular junction and apoptosis in FUS-ALS iPSC-derived muscle-nerve co-cultures
Professor Alessandro Rosa

HCB-13 WITHDRAWN

BIO-05 The first evaluation of calretinin in the spinal axons encompassed in anterolateral funiculi outside the corticospinal tract and cerebrospinal fluids of ALS patients
Dr Shintaro Hyashi

BIO-06 WITHDRAWN

BIO-07 Benchmarking Proteome of Extracellular Vesicles From Plasma Of fALS-Associated SOD1 Mutant Patients And SOD1 Mutant Healthy Controls
Dr Aslihan Gunel

BIO-08 First evidence of altered Gas6-Axl signaling and correlation between sAXL blood levels and clinical decline in ALS
Dr Marco Peviani

BIO-09 Premorbid primary care blood biomarker alterations support a metabolic prodrome in amyotrophic lateral sclerosis
Dr Alexander Thompson
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.45</td>
<td>Inhibition of glucosylceramides improves cell viability and TDP-43 mislocalisation in ALS iPSC-LMNs</td>
<td>Miss Leanne Jiang</td>
</tr>
<tr>
<td>14.00</td>
<td>Investigating novel gene therapy approaches to target RAN-translation of pathological C9ORF72 repeat transcripts in ALS/FTD</td>
<td>Miss Bridget Benson</td>
</tr>
<tr>
<td>14.15</td>
<td>The identification of SCFV’S that bind to TDP-43 and prevent its induced aggregation as a potential therapy for ALS</td>
<td>Professor Hélène Blasco</td>
</tr>
<tr>
<td>14.30</td>
<td>The feeding behaviour of Amyotrophic Lateral Sclerosis mouse models is modulated by the Ca2+-activated KCa3.1 channels</td>
<td>Mrs Germana Cocozza</td>
</tr>
<tr>
<td>14.45</td>
<td>Novel functionalized nanoparticles targeted to 18KDa translocator protein (TSPO) to track and modulate neuroinflammation in animal models of familial Amyotrophic Lateral Sclerosis</td>
<td>Mr Andrea Gazzano</td>
</tr>
<tr>
<td>15.00</td>
<td>Effects of therapeutic hypothermia in an animal model of Amyotrophic Lateral Sclerosis</td>
<td>Dr Laura Pasetto</td>
</tr>
<tr>
<td>15.15</td>
<td>VecTabs® and advanced human in-vitro models: targeting TDP-43 aggregates and oxidized phosphocholines in Amyotrophic Lateral Sclerosis</td>
<td>Dr Andreia Duarte</td>
</tr>
<tr>
<td>15.30</td>
<td>A monocentric case series of Hirayama’s disease: clinical, neurophysiological, imaging features and differences with Amyotrophic Lateral Sclerosis</td>
<td>Dr Sara Cabras</td>
</tr>
<tr>
<td>15.45</td>
<td>Clinical utility of structural and diffusion brainstem analysis in predicting bulbar and respiratory dysfunction</td>
<td>Dr Mohammed Khaymuza</td>
</tr>
<tr>
<td>16.00</td>
<td>EPI-589 early Phase 2 Investigator-initiated Clinical trial for ALS (EPIC-ALS)</td>
<td>Dr Shotaro Haji</td>
</tr>
<tr>
<td>16.15</td>
<td>TUDCA as disease modifier for ALS: time will tell truth</td>
<td>Dr Antoniagela Cocco</td>
</tr>
<tr>
<td>16.30</td>
<td>First in human phase 1/2a study evaluating the safety and efficacy of the Akt activator, IPI344 in ALS</td>
<td>Professor Marc Gotkin</td>
</tr>
<tr>
<td>16.45</td>
<td>Design of an international, phase 3, randomized, placebo-controlled trial with daily oral edaravone (fnp122) in als: the adore study</td>
<td>Dr Ruben van Eijk</td>
</tr>
<tr>
<td>17.00</td>
<td>Remote monitoring of accelerometry for amyotrophic lateral sclerosis detects differences in disease progression and survival</td>
<td>Mr JWJ van Unnik</td>
</tr>
<tr>
<td>17.15</td>
<td>Shifting the Paradigm – PrimeC: A Potential Disease-Modifying Treatment for ALS Driven by Novel Biomarkers Measuring Mechanism of Action</td>
<td>Dr Shiran Zimri</td>
</tr>
<tr>
<td>17.30</td>
<td>Protein structure based FUS mutational subtypes are linked with subcellular mislocalization and age at onset in amyotrophic lateral sclerosis</td>
<td>Mr Wanli Yang</td>
</tr>
<tr>
<td>17.45</td>
<td>When rare gets rarer: five reports of association between ALS and other uncommon conditions from a large cohort of patients in Central Italy</td>
<td>Dr Francesca Bianchi</td>
</tr>
<tr>
<td>18.00</td>
<td>A patients with ALS and TBK1 loss of function mutation: a case report</td>
<td>Dr Lorenzo Fontanelli</td>
</tr>
<tr>
<td>18.15</td>
<td>Phenotype-specific gene expression patterns identification through transcriptome-phenotype investigation in unmutated sporadic ALS patients</td>
<td>Dr Maria Garofalo</td>
</tr>
<tr>
<td>18.30</td>
<td>Traditional Methods of Quantifying Upper Limb Function in ALS and the Need for Objective Solutions</td>
<td>Dr Conor Hayden</td>
</tr>
<tr>
<td>18.45</td>
<td>Defining mild cognitive and behavioural impairment in pre-symptomatic ALS/FTD</td>
<td>Dr Caroline McHutchison</td>
</tr>
<tr>
<td>19.00</td>
<td>Relevance of respiratory tests in determining respiratory involvement in ALS</td>
<td>Dr Susana Pinto</td>
</tr>
<tr>
<td>19.15</td>
<td>Measuring Mechanism of Action for ALS Driven by Novel Biomarkers Potential Disease-Modifying Treatment</td>
<td>Professor Hélène Blasco</td>
</tr>
<tr>
<td>19.30</td>
<td>Quantifying network dysfunction underpinning social cognition impairments in ALS with EEG</td>
<td>Dr Roisin McMackin</td>
</tr>
<tr>
<td>19.45</td>
<td>Experiences, coping strategies and support needs of family caregivers of ALS-patients post-bereavement</td>
<td>Mrs Sabina Pujic</td>
</tr>
<tr>
<td>20.00</td>
<td>Cognition in the Course of ALS – a Meta-Analysis</td>
<td>Mrs Julia Finsel</td>
</tr>
<tr>
<td>20.15</td>
<td>Utility of three-dimensional (3D) motion capture in monitoring disease progression in amyotrophic lateral sclerosis (ALS)</td>
<td>Ms Akiko Goto</td>
</tr>
<tr>
<td>20.30</td>
<td>Robot-assisted training using HAL ameliorates gait ability in patients with amyotrophic lateral sclerosis</td>
<td>Miss Harumi Morioka</td>
</tr>
<tr>
<td>20.45</td>
<td>Satisfaction with health-associated support system in Germany and Poland from the perspective of patients with amyotrophic lateral sclerosis, their caregivers and physicians</td>
<td>Dr Krzysztof Barć</td>
</tr>
<tr>
<td>21.00</td>
<td>Paraneoplastic motor neuron disease with anti-CV2 antibodies</td>
<td>Sra Maria Dolores Calabria Gallego</td>
</tr>
<tr>
<td>21.15</td>
<td>The role of maximal voluntary ventilation in evaluating respiratory function of ALS patients</td>
<td>Professor Mamede Alves De Carvalho</td>
</tr>
<tr>
<td>21.30</td>
<td>Making her end of life her own: further reflections on supporting a loved one with motor neurone disease</td>
<td>Dr Denise Harris</td>
</tr>
<tr>
<td>21.45</td>
<td>Feasibility and acceptability of the real-world implementation of Telehealth in Motor Neuron Disease (TiM) service in two specialist MND centres.</td>
<td>Dr Liam Knox</td>
</tr>
<tr>
<td>22.00</td>
<td>‘Gastrostomy Tube: Is it for Me?’ Development and pilot testing of a web-based patient decision aid for people with motor neurone disease considering a gastrostomy tube (DIAMoND Study)</td>
<td>Dr Sally Wheelwright</td>
</tr>
</tbody>
</table>
### SESSION 3

#### METABOLISM

**Chairs:** B Dickie (UK) A Al-Chalabi (UK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Parallel Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 – 14.25</td>
<td>C06 Investigating the role of hypermetabolism in ALS</td>
</tr>
<tr>
<td></td>
<td><em>S Ngo (Australia)</em></td>
</tr>
<tr>
<td>14.25 – 14.40</td>
<td>C07 Dysregulated energy metabolism related to worse prognosis in ALS</td>
</tr>
<tr>
<td></td>
<td><em>J He (China)</em></td>
</tr>
<tr>
<td>14.40 – 14.55</td>
<td>C08 An 18F-FDG-PET study exploring the metabolic signature of pure bulbar and pure spinal ALS</td>
</tr>
<tr>
<td></td>
<td><em>F Di Pede (Italy)</em></td>
</tr>
<tr>
<td>14.55 – 15.10</td>
<td>Discussion/Questions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Networking Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.10 – 15.40</td>
<td>Networking Event</td>
</tr>
</tbody>
</table>

### SESSION 4

#### CELL BASED MODELS

**Chairs:** G Tyzak (UK) N Cole (UK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Parallel Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.40 – 16.05</td>
<td>C09 iPSC-derived models for compound screening and the identification of new therapeutic strategies</td>
</tr>
<tr>
<td></td>
<td><em>K Roet (USA)</em></td>
</tr>
<tr>
<td>16.05 – 16.20</td>
<td>C10 Sporadic ALS motor neurons recapitulate neuronal vulnerability</td>
</tr>
<tr>
<td></td>
<td><em>B Turner (Australia)</em></td>
</tr>
<tr>
<td>16.20 – 16.35</td>
<td>C11 Reduced C9orf72 expression exacerbates poly-GR toxicity in patient iPSC-derived motor neurons</td>
</tr>
<tr>
<td></td>
<td><em>T Dane (USA)</em></td>
</tr>
<tr>
<td>16.35 – 16.50</td>
<td>Discussion/Questions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Break</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.50 – 17.05</td>
<td>Break</td>
</tr>
</tbody>
</table>
SESSION 5

DISEASE PRESENTATION AND RISK

Chairs: A Thompson (UK) A Al-Chalabi (UK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.05 – 17.25</td>
<td>C12</td>
<td>Identifying risk factors using Mendelian Randomization</td>
<td>G Davey Smith (UK)</td>
</tr>
<tr>
<td>17.25 – 17.45</td>
<td>C13</td>
<td>Traumatic Brain Injury as a risk factor for neurodegenerative disease</td>
<td>C Tartaglia (Canada)</td>
</tr>
<tr>
<td>17.45 – 18.05</td>
<td>C14</td>
<td>Mild motor impairment and prodromal markers</td>
<td>M Benatar (USA)</td>
</tr>
<tr>
<td>18.05 – 18.20</td>
<td></td>
<td>Discussion/Questions</td>
<td></td>
</tr>
</tbody>
</table>

PARALLEL SESSION

17.05 – 17.50 Sponsored Parallel Session 3 (non-CME)
Thursday 8 December 2022

SESSION 6

**GENETICS AND GENOMICS**

*Chairs: C Vance (UK) A Al-Chalabi (UK)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 – 14.25</td>
<td>C15</td>
<td>Decoding gene regulatory networks in ALS</td>
<td>J Kirby (UK)</td>
<td>14.00 – 14.45</td>
<td>Sponsored Parallel Session 4 (non-CME)</td>
</tr>
<tr>
<td>14.25 – 14.40</td>
<td>C16</td>
<td>Unsupervised hierarchical clustering of postmortem motor cortex expression data identifies distinct molecular phenotypes which replicate the major mechanisms of ALS pathogenesis</td>
<td>H Marriott (UK)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.40 – 14.55</td>
<td>C17</td>
<td>Interactions between genetic modifiers of survival in ALS: a population based study</td>
<td>A Chio (Italy)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.55 – 15.10</td>
<td>Discussion/Questions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.10 – 15.25</td>
<td>BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SESSION 7

**RNA AND PROTEIN PROCESSING**

*Chairs: M Hallegger (UK) N Cole (UK)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.25 – 15.50</td>
<td>C18</td>
<td>Protein chaperones as a therapeutic target for ALS</td>
<td>H Durham (Canada)</td>
</tr>
<tr>
<td>15.50 – 16.15</td>
<td>C19</td>
<td>MicroRNA dysregulation in motor neuron disease</td>
<td>E Hornstein (Israel)</td>
</tr>
<tr>
<td>16.15 – 16.30</td>
<td>C20</td>
<td>Diminished miRNA activity is associated with aberrant cytoplasmic intron retention in ALS pathogenesis</td>
<td>H Crerar (UK)</td>
</tr>
<tr>
<td>16.30 – 16.45</td>
<td>Discussion/Questions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.45 – 17.00</td>
<td>BREAK</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
LIVE POSTER SESSION C

17.00 – 18.30 GMT

EPI-09 Kidney Function (eGFR MDRD) in ALS Patients
Mr Matteo Locatelli

EPI-10 Poliomyelitis Survivors in the Time of a Covid-19 Pandemic
Miss Jeyce Nogueira

EPI-11 Estimates of C9orf72 Statistics drawn from prior publications, including estimated Life Expectancy for Genetic Carriers, Estimated Incidence of C9orf72 ALS and FTD Diagnoses, Estimated Genetic Carrier and At Risk Population and others.
Ms Jean Swidler

EPI-12 Early initiation of riluzole may improve absolute survival in amyotrophic lateral sclerosis
Dr Nishim Thakore

GEN-17 Fine-tuning a molecular diagnosis algorithm for patients with ALS and FTD
Dr Daniel Borrego Hernández

GEN-18 Exploring the role of HERV-K integrations in amyotrophic lateral sclerosis
Mr Harry Bowles

GEN-19 SOD1 D91A variant in the southernmost tip of Europe: a heterozygous ALS patient resident on the island of Gozo
Professor Ruben Cauchi

GEN-20 Allele genotype of a SINE-VNTR-Alu (SVA) retrotransposon correlates with differential gene expression at the MAPT locus
Mr Alexander Fröhlich

GEN-21 Utilising genetic data and quality of life metrics within the TONiC initiative to better predict patient outcome, progression and severity in ALS
Dr Ben Middlehurst

GEN-22 Targeted long-read sequencing of C9orf72 in blood of patients with ALS
Mr Evan Udine

GEN-23 WITHDRAWN

IVT-12 iPSC-derived motor and sensory neurons have distinct molecular profiles but share axonal vulnerability due to the C9orf72 hexanucleotide repeat expansion
Dr Jakub Scaber

IVT-13 Characterization of PPIA/EMMPRIN pathway in the peripheral nervous system of SOD1G93A model of Amyotrophic Lateral Sclerosis
Miss Marion Boyer

IVT-14 Using PRMT Inhibition to Abrogate Dipeptide Repeat Protein Toxicity in C9orf72-Mediated ALS: A Proteomics Assessment of Post-Translational Modifications
Ms Anna Gill

IVT-15 Traumatic injury exacerbates neuropathology in C9orf72 ALS/FTD motor neurons
Mr. Eric Martin

IVT-16 Effects of arginine methylation state on the subcellular localization of C9orf72 repeat expansion associated toxic dipeptide repeat proteins.
Ms Kaly Mueller

IVT-17 Cytoplasmic accumulation of FUS in adult neurons prevents establishment of social memory but preserves motor function
Dr Luc Dupuis

IVT-18 Imaging the spinal cord neurodegeneration of the TDP-43-A315T ALS mouse model: relationship between MRI and TDP-43 aggregates
Dr Débora Lanznaster

IVT-19 Characterization of PPIA/EMMPRIN pathway in the peripheral nervous system of SOD1G93A model of Amyotrophic Lateral Sclerosis
Miss Sarah Holbrook

IVT-20 Early initiation of riluzole may improve absolute survival in amyotrophic lateral sclerosis
Dr Nishim Thakore

IVT-21 Utilising genetic data and quality of life metrics within the TONiC initiative to better predict patient outcome, progression and severity in ALS
Dr Ben Middlehurst

IVT-22 Targeted long-read sequencing of C9orf72 in blood of patients with ALS
Mr Evan Udine

IVT-23 WITHDRAWN

HCB-15 Crosstalk between NEAT1_1 IncRNA and TDP-43 in ALS
Dr Tatyana Shelkovnikova

HCB-16 Dynamic Expression Profiles of Stressed iPSC-MNs from C9orf72-ALS Patients by Translating Ribosome Affinity Purification (TRAP)
Dr Yinyan Xu

HCB-17 Discovery of novel small molecule Cu(II) complexes using a genome edited iPSc-based phenotypic screening platform
Dr Kyle Denton

HCB-18 SIRT1 is associated with the alleviation of DPR pathology in C9orf72-associated disease
Ms Sophie Imhof

HCB-19 Stabilizing Microtubules Rescues Disrupted Nucleocytoplasmic Transport in Loss-of-Function Models of the ALS Gene NEK1
Dr Jacob Mann

HCB-20 Proteome-Wide Degradation Dynamics in ALS SOD1 Patient Neurons Reveals Disrupted VCP Homeostasis
Dr Konstantinos Tsioras

BIO-10 Integrated deep proteomics of cerebral spinal fluid for biomarker identification in ALS
Dr Elizabeth Dellar

BIO-11 Inflammasome genes expression as biomarkers in ALS and FTD patients
Miss Laura Expósito Blázquez

BIO-12 Characterisation of the role of the gut-brain axis in the pathophysiology and progression of motor neuron disease
Miss Iman Geelani Khwaja

BIO-13 Erythrocyte membrane properties in patients with ALS
Dr Ana Catarina Pronto Laborinho

BIO-14 WITHDRAWN

TST-15 Engrailed-1 homeoprotein is a non-cell autonomous neurotrophic factor
for motoneurons
Dr Stephanie Elizabeth Vargas Abonce

TST-16 QRL-201: A Stathmin-2 splice-switching antisense oligonucleotide for the treatment of ALS
Ms Taylor Gray

TST-17 Preclinical Characterization of Prosetin, A Novel, Brain-Penetrant, Clinical-Stage MAP4K Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis
Dr Emily Lowry

TST-18 Targeting the NFkb pathway as a therapeutic strategy for stabilizing dendritic structure in an ALS-FUS mouse model
Mrs Mari Carmen Pelaez

TST-19 Hydrogen Peroxide and Amyotrophic Lateral Sclerosis: From Biochemistry to Pathophysiology
Mr Nitesh Sanghavi

TST-20 Targeting neuregulin1 on microglia to slow or stop ALS
Professor Fei Song

TST-21 Development of TDP-43 inhibitors for the treatment of ALS, FTD, and Alzheimer’s disease
Dr Chengliang Zhang

TST-22 Phase 3b, Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Oral Edaravone Administered Over 48 Weeks in Patients with Amyotrophic Lateral Sclerosis (MT-1186-A02)
Dr Alejandro Salah

TST-23 ENCLALS Predictive Survival Model in FORTITUDE-ALS
Dr Tyrell Simkins

TST-24 Update on an International Phase 3 Trial Evaluating Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (PHOENIX)
Professor Leonard van den Berg

TST-25 Eligibility, prescription, and dispensation of riluzole and Radicava(R) for newly diagnosed people with Amyotrophic Lateral Sclerosis (ALS): A methodological exploration
Ms Juliette Ortholand

TST-26 International survey of trials for motor neuron disease: An exploration
Mr Jochem Helleman

Dr Angela Genge

TST-28 Operationalizing meaningful participant engagement in ALS research: Early lessons from CAPTURE ALS
Dr Wendy Johnston

TST-29 Using asynchronous online focus groups to improve access to research for people affected by amyotrophic lateral sclerosis (ALS): A methodological exploration
Ms Westerly Luth

TST-30 Interaction of gender and nQ as an objective biomarker to assess fine motor impairment in people with ALS
Ms Juliette Ortholand

TST-31 Evaluating activity patterns in patients with motor neuron disease
Dr Andrew Geronimo

TST-32 Wearable sensors for tracking motoneuron activity as an objective biomarker
Ms Juliette Ortholand

TST-33 The HEALEY ALS Platform Trial: Results of Regimens A-D
Dr Merr Cudkowicz
## LIVE POSTER SESSION D

**Friday 9 December 2022**

<p>| 12.15 – 13. GMT |<br />
|-----------------|------------------|
| EPI-13 Time interval between age at retirement from soccer and the onset of ALS in the Spanish league: a literature review and meta-analysis. | Miss Deborah Ness |
| EPI-14 The influence of agricultural areas on ALS risk and phenotype: a population-based study | Miss Effective |<br />
| EPI-15 Presymptomatic geographical distribution of patients with Amyotrophic Lateral Sclerosis: a population-based cluster analysis. | Miss Effortless |
| GEN-24 Reduced-penetrance Huntington's disease-causing alleles with 39 CAG trinucleotide repeats could be a genetic factor of amyotrophic lateral sclerosis | Miss Effortlessly |
| GEN-25 Discovering novel MND causal mutations through comprehensive assessment of complex genomic variant types | Miss Effortlessly |
| GEN-17 Developing a molecular platform for the rapid functional study of novel oligogenic MND candidate genes in vitro | Miss Effortlessly |
| IVT-18 Human in vitro models of TDP-43 proteinopathy for drug screening approaches | Miss Effortlessly |
| IVT-19 DNA Damage Defects are Rescued by Enhancing Chromatin Ubiquitination and DRRNAs Biogenesis in ALS Cellular Model System | Miss Effortlessly |
| IVT-20 TDP-43 dysregulation and STMN-2 mis-splicing upon proteasomal inhibition in potential iPSC-derived neuronal ALS model | Miss Effortlessly |
| IVT-21 Investigating sporadic ALS using human iPSC-derived cells | Miss Effortlessly |
| IVV-20 Hyperactivity of Purkinje cell and motor deficits in C9orf72 knockout mice | Miss Effortlessly |
| IVV-21 Comparison of C9orf72 BAC mice on Jackson and Janvier FVB Backgrounds | Miss Effortlessly |
| HCB-21 Divergent cerebellar transcriptome in amyotrophic lateral sclerosis cases with greater burden of pTDP-43 neuropathology | MissEffortlessly |
| HCB-22 Iron pathways are perturbed and accumulation overlaps with a shifted lipid profile in the CNS of human MND cases | Miss Effortlessly |
| HCB-23 Cell autonomous dysfunction in VCP mutant hiPSC derived microglia | Miss Effortlessly |
| HCB-24 Investigating the role of neuroinflammation in C9ORF72 ALS using stem cell models | Miss Effortlessly |
| HCB-25 Single-Cell Proteomics and Lipidomics of Betz and Purkinje Cells in Human Motor Neuron Disease Brain | Miss Effortlessly |
| HCB-26 C9ORF72-ALS patient-derived iPSC microglia display pathological features associated with the hexanucleotide repeat expansion and have a pro-inflammatory profile | Miss Effortlessly |
| HCB-27 Meta-analysis of ALS astrocytes reveals inflammatory reactive states | Miss Effortlessly |
| BIO-15 TDP-43 accumulations within intramuscular nerve bundles of ALS patients | Miss Effortlessly |
| BIO-16 WITHDRAWN | Miss Effortlessly |
| BIO-17 Extracellular Vesicle Sphingomyelins as Biomarkers in Amyotrophic Lateral Sclerosis | Miss Effortlessly |
| BIO-18 Investigating the role of autoantibodies against Neurofilaments in neurodegeneration | Miss Effortlessly |
| BIO-19 WITHDRAWN | Miss Effortlessly |</p>
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TST-22</strong></td>
<td>Targeting intracellular TDP-43 using SCFV’S vectorized to pegylated spions</td>
<td>Miss Yara Al Ojaimi</td>
</tr>
<tr>
<td><strong>TST-23</strong></td>
<td>Orexin-dependent sleep impairment in mouse models of ALS</td>
<td>Dr Simon J. Guillot</td>
</tr>
<tr>
<td><strong>TST-24</strong></td>
<td>Development of a methodology for the bio-synthesis of a novel “drug-like” cell-permeable peptide inhibiting the SRSF1-dependent nuclear export of C9ORF72-repeat transcripts in ALS/FTD</td>
<td>Mr Aytac Gul</td>
</tr>
<tr>
<td><strong>TST-25</strong></td>
<td>A novel “drug-like” therapeutic strategy to inhibit the SRSF1-dependent nuclear export of pathological C9ORF72-repeat transcripts in ALS/FTD</td>
<td>Dr Ya-Hui Lin</td>
</tr>
<tr>
<td><strong>TST-26</strong></td>
<td>The role of TUDCA in Neurodegeneration</td>
<td>Mrs Maria Lo Giudice</td>
</tr>
<tr>
<td><strong>TST-27</strong></td>
<td>Inhibition of class I histone deacetylases ameliorates TDP-43 pathology in experimental models of ALS</td>
<td>Dr Serena Scozzari</td>
</tr>
<tr>
<td><strong>IMG-10</strong></td>
<td>Cortical Hyperexcitability Associated Glutamate Abnormality in ALS</td>
<td>Dr Sicong Tu</td>
</tr>
<tr>
<td><strong>IMG-11</strong></td>
<td>Home-based electroencephalography in the assessment of cognitive decline in Amyotrophic Lateral Sclerosis and Frontal Temporal Dementia</td>
<td>Dr Emmet Costello</td>
</tr>
<tr>
<td><strong>IMG-12</strong></td>
<td>Noradrenaline deficiency as a driver of cortical hyperexcitability in amyotrophic lateral sclerosis</td>
<td>Dr Caroline Rouaux</td>
</tr>
<tr>
<td><strong>IMG-13</strong></td>
<td>Exploring the split hand phenomenon with the neurophysiological index</td>
<td>Dr Cláudia Santos Silva</td>
</tr>
<tr>
<td><strong>CLT-25</strong></td>
<td>Evaluation of the usability of the Atalante exoskeleton in the physical therapy of ALS patients</td>
<td>Mrs Ghida Trad</td>
</tr>
<tr>
<td><strong>CLT-26</strong></td>
<td>Long term survival of participants in the mesenchymal stromal stem cells transplantation in amyotrophic lateral sclerosis.</td>
<td>Dr Fabiola De Marchi</td>
</tr>
<tr>
<td><strong>CLT-27</strong></td>
<td>Estimating resting energy expenditure in people living with Amyotrophic Lateral Sclerosis</td>
<td>Ms Sarah Roscoe</td>
</tr>
<tr>
<td><strong>CLT-28</strong></td>
<td>A pilot phase II study to evaluate the effect of salbutamol on walking capacity in ambulatory ALS patients</td>
<td>Dr Giorgia Querin</td>
</tr>
<tr>
<td><strong>DSP-22</strong></td>
<td>miR-181 in plasma and CSF is a prognostic biomarker for ALS</td>
<td>Dr Iddo Magen</td>
</tr>
<tr>
<td><strong>DSP-23</strong></td>
<td>Interest of arterial blood gas parameters as prognostic markers in amyotrophic lateral sclerosis</td>
<td>Dr Hugo Alarcan</td>
</tr>
<tr>
<td><strong>DSP-24</strong></td>
<td>The role of peripheral immunity in Amyotrophic Lateral Sclerosis</td>
<td>Dr Maurizio Grassano</td>
</tr>
<tr>
<td><strong>DSP-25</strong></td>
<td>The flail-arm syndrome: the influence of phenotypic features</td>
<td>Dr Marta Gromicho</td>
</tr>
<tr>
<td><strong>DSP-26</strong></td>
<td>ALS and anxiety - a prognostic indicator</td>
<td>Dr Mariam Kekenadze</td>
</tr>
<tr>
<td><strong>DSP-27</strong></td>
<td>Cognitive phenotypes in ALS relate to distinct longitudinal changes of functional 7networks disruption: a resting-state EEG study</td>
<td>Ms Marjorie Metzger</td>
</tr>
<tr>
<td><strong>CMS-26</strong></td>
<td>Effects of e-learning as support communication for people with ALS among students in multiple healthcare disciplines: Assessment of single-session effects through pre- and post-tests.</td>
<td>Mr Tekemasa Ishikawa</td>
</tr>
<tr>
<td><strong>CMS-27</strong></td>
<td>Noradrenaline deficiency as a driver of cortical hyperexcitability in amyotrophic lateral sclerosis</td>
<td>Dr Caroline Rouaux</td>
</tr>
<tr>
<td><strong>CMS-28</strong></td>
<td>Apathy in Amyotrophic Lateral Sclerosis, and how it influences trial participation</td>
<td>MSc Juliette Foucher</td>
</tr>
<tr>
<td><strong>CMS-29</strong></td>
<td>Italian adaptation of the Beaumont Behavioural Inventory (BBI): psychometric properties and clinical usability</td>
<td>Mrs Laura Peotta</td>
</tr>
<tr>
<td><strong>CMS-30</strong></td>
<td>Stigma experienced by ALS patients and their caregivers: A mixed-methods study</td>
<td>Miss Ana Paula Trucco</td>
</tr>
<tr>
<td><strong>CMS-31</strong></td>
<td>Evaluation of smartphone-based cough data in amyotrophic lateral sclerosis as a potential predictor functional disability</td>
<td>Mr Pedro Rocha</td>
</tr>
<tr>
<td><strong>CMS-32</strong></td>
<td>A systematic review of factors associated with grief in informal carers of people living with Motor Neurone Disease</td>
<td>Dr Marion Sommers-Spijkerman</td>
</tr>
<tr>
<td><strong>CMS-33</strong></td>
<td>Cognitive phenotypes in ALS relate to distinct longitudinal changes of functional 7networks disruption: a resting-state EEG study</td>
<td>Ms Marjorie Metzger</td>
</tr>
<tr>
<td><strong>CMS-34</strong></td>
<td>A pilot phase II study to evaluate the effect of salbutamol on walking capacity in ambulatory ALS patients</td>
<td>Dr Giorgia Querin</td>
</tr>
<tr>
<td><strong>CMS-35</strong></td>
<td>Evaluation of the usability of the Atalante exoskeleton in the physical therapy of ALS patients</td>
<td>Mrs Ghida Trad</td>
</tr>
<tr>
<td><strong>CMS-36</strong></td>
<td>Estimating resting energy expenditure in people living with Amyotrophic Lateral Sclerosis</td>
<td>Ms Sarah Roscoe</td>
</tr>
<tr>
<td><strong>CMS-37</strong></td>
<td>A pilot phase II study to evaluate the effect of salbutamol on walking capacity in ambulatory ALS patients</td>
<td>Dr Giorgia Querin</td>
</tr>
<tr>
<td><strong>CMS-38</strong></td>
<td>The role of peripheral immunity in Amyotrophic Lateral Sclerosis</td>
<td>Dr Maurizio Grassano</td>
</tr>
<tr>
<td><strong>CMS-39</strong></td>
<td>The flail-arm syndrome: the influence of phenotypic features</td>
<td>Dr Marta Gromicho</td>
</tr>
<tr>
<td><strong>CMS-40</strong></td>
<td>ALS and anxiety - a prognostic indicator</td>
<td>Dr Mariam Kekenadze</td>
</tr>
<tr>
<td><strong>CMS-41</strong></td>
<td>Cognitive phenotypes in ALS relate to distinct longitudinal changes of functional 7networks disruption: a resting-state EEG study</td>
<td>Ms Marjorie Metzger</td>
</tr>
<tr>
<td><strong>CMS-42</strong></td>
<td>Apathy in Amyotrophic Lateral Sclerosis, and how it influences trial participation</td>
<td>MSc Juliette Foucher</td>
</tr>
<tr>
<td><strong>CMS-43</strong></td>
<td>Italian adaptation of the Beaumont Behavioural Inventory (BBI): psychometric properties and clinical usability</td>
<td>Mrs Laura Peotta</td>
</tr>
<tr>
<td><strong>CMS-44</strong></td>
<td>Stigma experienced by ALS patients and their caregivers: A mixed-methods study</td>
<td>Miss Ana Paula Trucco</td>
</tr>
<tr>
<td><strong>CMS-45</strong></td>
<td>Evaluation of smartphone-based cough data in amyotrophic lateral sclerosis as a potential predictor functional disability</td>
<td>Mr Pedro Rocha</td>
</tr>
<tr>
<td><strong>CMS-46</strong></td>
<td>Italian adaptation of the Beaumont Behavioural Inventory (BBI): psychometric properties and clinical usability</td>
<td>Mrs Laura Peotta</td>
</tr>
<tr>
<td><strong>CMS-47</strong></td>
<td>Stigma experienced by ALS patients and their caregivers: A mixed-methods study</td>
<td>Miss Ana Paula Trucco</td>
</tr>
<tr>
<td><strong>CMS-48</strong></td>
<td>Evaluation of smartphone-based cough data in amyotrophic lateral sclerosis as a potential predictor functional disability</td>
<td>Mr Pedro Rocha</td>
</tr>
<tr>
<td><strong>CMS-49</strong></td>
<td>Apathy in Amyotrophic Lateral Sclerosis, and how it influences trial participation</td>
<td>MSc Juliette Foucher</td>
</tr>
<tr>
<td><strong>CMS-50</strong></td>
<td>Italian adaptation of the Beaumont Behavioural Inventory (BBI): psychometric properties and clinical usability</td>
<td>Mrs Laura Peotta</td>
</tr>
<tr>
<td><strong>CMS-51</strong></td>
<td>Stigma experienced by ALS patients and their caregivers: A mixed-methods study</td>
<td>Miss Ana Paula Trucco</td>
</tr>
<tr>
<td><strong>CMS-52</strong></td>
<td>Evaluation of smartphone-based cough data in amyotrophic lateral sclerosis as a potential predictor functional disability</td>
<td>Mr Pedro Rocha</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>13.45 – 14.00</strong></td>
<td>BREAK</td>
<td></td>
</tr>
</tbody>
</table>
### SESSION 8

**NEUROINFLAMMATION**

*Chairs: A Malaspina (UK) and N Cole (UK)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00</td>
<td>C21</td>
<td>Modelling neuroinflammation in ALS</td>
<td>J Kriz (Canada)</td>
<td>14.00</td>
</tr>
<tr>
<td>14.20</td>
<td>C22</td>
<td>Suppressing Neuroinflammation: Regulatory T Lymphocyte Immunomodulatory Therapy for ALS</td>
<td>S Appel (USA)</td>
<td>14.20</td>
</tr>
<tr>
<td>14.40</td>
<td>C23</td>
<td>Molecular signatures of neuroinflammation in patient tissue across sporadic, SOD1 and C9orf72 ALS cohorts</td>
<td>O Rifai (UK)</td>
<td>14.40</td>
</tr>
<tr>
<td>14.55</td>
<td></td>
<td><strong>Discussion/Questions</strong></td>
<td></td>
<td>14.55</td>
</tr>
<tr>
<td>15.10</td>
<td></td>
<td><strong>BREAK</strong></td>
<td></td>
<td>15.10</td>
</tr>
</tbody>
</table>

### SESSION 9

**TRIAL DESIGN AND CLINICAL ENDPOINTS**

*Chairs: L Bruijn (UK) A Al-Chalabi (UK)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.25</td>
<td>C24</td>
<td>Improving clinical endpoints in therapeutic trials for ALS</td>
<td>R van Eijk (Netherlands)</td>
<td>15.25</td>
</tr>
<tr>
<td>15.45</td>
<td>C25</td>
<td>Improving ALS clinical trial design</td>
<td>T Ferguson/S Fradette (USA)</td>
<td>15.45</td>
</tr>
<tr>
<td>16.05</td>
<td>C26</td>
<td>Registry of Validated Endpoints in ALS (REVEALS): Results from a multi-centre prospective study of respiratory measures and their clinical meaningfulness</td>
<td>D Meldrum (Ireland)</td>
<td>16.05</td>
</tr>
<tr>
<td>16.20</td>
<td></td>
<td><strong>Discussion/Questions</strong></td>
<td></td>
<td>16.20</td>
</tr>
<tr>
<td>16.35</td>
<td></td>
<td><strong>BREAK</strong></td>
<td></td>
<td>16.35</td>
</tr>
</tbody>
</table>
## SESSION 10

### CLOSING SESSION

**Chairs:** B Dickie (UK) A Al-Chalabi (UK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.50 – 16.55</td>
<td>Invitation to Basel 2023</td>
<td></td>
</tr>
<tr>
<td>16.55 – 17.25</td>
<td>BrainGate: Clinical trials in intracortical brain-computer interfaces toward the restoration of communication and mobility</td>
<td>L Hochberg (USA)</td>
</tr>
<tr>
<td>17.25 – 17.35</td>
<td>Discussion/Questions</td>
<td></td>
</tr>
<tr>
<td>17.35 – 17.55</td>
<td>Healey Center Prize and Lalji Family Award</td>
<td></td>
</tr>
<tr>
<td>17.55 – 18.15</td>
<td>Final thoughts and Prize Draw</td>
<td></td>
</tr>
</tbody>
</table>
Frequently Asked Questions (FAQ)

How do I login to the platform?
Approximately five days prior to the Symposium you will receive an email with your login details for the virtual platform, as well as instructions on how to login. We will also be sending out reminders on each morning of the Symposium. If you do have any issues logging into the virtual platform on the day, please use the 'Support' icon in the bottom righthand corner of the login page.

How do I update my contact details and sharing preferences?
Once you are signed into the virtual platform, you will be prompted to review and update your profile, photo and privacy settings. To choose what information you share in the meeting hub, scroll to the bottom of 'My Settings' and select the information you are happy to share with other attendees. If you would like to access this later, please click on your profile photo at the top right of the screen and select 'My Settings'.

How do I navigate the timeline?
Sessions and functions that are happening each day are listed in the timeline in chronological order. You can click on any of the items in the timeline to view session information and join the session or function. Once you are in a session, always use the 'Back to timeline' button to get back to the homepage.

What is the Exhibitor Hall?
You can visit 'Exhibitor Hall' at any time of the day. Here, you can search and browse through the list of exhibitors. Clicking on the View Button lets you review the Exhibitor’s Information and download any available brochures. You can also choose to connect with members of the Exhibitor team via Meeting Hub. If the exhibition is open and the exhibitor’s staff are online, you can request a live meeting and you will be placed in a queue. You can always see your position in the queue and when you reach the top of the queue a video meeting with the selected member of the exhibitor’s team will begin.

What is a Live Poster Session?
During the Live Poster Sessions, you will be able to browse and search for poster presentations that interest you. Click on the Poster Presentation to find out more information and enter to view the live presentation. When the presenter adds you to their presentation, your microphone will be unmuted. You can mute and unmute your microphone at any time if you wish to interact and ask the author questions.

Where do I go for technical support?
The quickest way to talk to us is by clicking on the red 'Support' icon in the top right of the screen. Our Support Team will be online and available to you.

What if I miss a session?
Don’t worry if you miss a session, all sessions will be available to watch on-demand the day after they have aired until 8 March 2023.

Will I receive a certificate of attendance?
Certificates of attendance will be emailed to all delegates after the conference has ended.
With grateful thanks to the following supporters of the 33rd International Symposium on ALS/MND

**PRINCIPAL SPONSOR**

Cytokinetics

**MAJOR SPONSORS**

AMYLYX® Biogen. ferrer

brainstorm cell therapeutics lifeArc

**KEY SPONSORS**

Apellis DenaLi

QurAlis Biotech

**GENERAL SPONSORS**

ARG
Join us in Basel, Switzerland
6 - 8 December 2023

Provisional abstract submission deadline: Tuesday 11 July 2023

For further information please contact:
Motor Neurone Disease Association
Telephone: +44 (0) 1604 611837
Email: symposium@mndassociation.org
Email: abstracts@mndassociation.org

www.mndassociation.org
www.symposium.mndassociation.org

Stay connected:

mndresearch
#alsmndsymp

© 2022 MND Association. Registered in England. Registered Charity no. 294354